TY - JOUR
T1 - Neoadjuvant Endocrine Therapy
T2 - Who Benefits Most?
AU - Grossman, Julie
AU - Ma, Cynthia
AU - Aft, Rebecca
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/1
Y1 - 2018/1
N2 - Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.
AB - Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.
KW - Aromatase inhibitors
KW - Estrogen receptor–positive breast cancer
KW - Neoadjuvant chemotherapy
KW - Neoadjuvant endocrine therapy
UR - http://www.scopus.com/inward/record.url?scp=85034228562&partnerID=8YFLogxK
U2 - 10.1016/j.soc.2017.07.008
DO - 10.1016/j.soc.2017.07.008
M3 - Review article
C2 - 29132556
AN - SCOPUS:85034228562
SN - 1055-3207
VL - 27
SP - 121
EP - 140
JO - Surgical Oncology Clinics of North America
JF - Surgical Oncology Clinics of North America
IS - 1
ER -